Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Vidur Patel"'
Autor:
Heather Jewell, Akinola Olumide Emmanuel, Albert Ruzo, Boris Gorovits, Caspian Harding, Bindu Varghese, Yonatan Lipsitz, Vidur Patel, Justine Cunningham, Sundeep Chandra, Victoria Duback, Hemant Chavan, Joohwan Kim, Michelle Nguyen-McCarty, Shannon Joyce, Aaron E. Foster, Carmela Passaro, Sergey Lyubinetsky, Lauren Pepper, Jason Rodriguez, Trevor McGill, Kelan Hlavaty, Misha Shamashkin, Paige Baldwin, Terry J. Fry, Shirisha Amatya, Carl Co, Salvatore Iovino, Jagesh V Shah, Hanane Ennajdaoui, Jess Elman, Allyse Mazzarelli, Donna Dambach, Kutlu G. Elpek, Carrie Rocca, Vasily Vagin, James Kaczmarek, Pattie Cruite, Michael Laska
Publikováno v:
Blood. 138:2769-2769
Introduction: Ex vivo manufactured chimeric antigen receptor (CAR) T cell therapies are highly effective for treating B cell malignancies. However, the complexity, cost and time required to manufacture CAR T cells limits access. To overcome conventio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46946ed5099ec17431d5555f68d3aae8
https://doi.org/10.1182/blood-2021-148709
https://doi.org/10.1182/blood-2021-148709
Autor:
Sergey Lyubinetsky, Allyse Mazarelli, Jess Elman, Kutlu G. Elpek, Patty Cruite, Caspian Harding, Trevor McGill, Donna Dambach, Terry J. Fry, Salvatore Iovino, Carmela Passaro, Vidur Patel, Shirisha Amatya, Albert Ruzo, Kelan Hlavaty, Victoria Duback, Lauren Pepper, Anna Liang, Avani Parikh, Akinola Olumide Emmanuel, Jagesh V Shah, Samantha Crocker, Michael Laska, Jason Rodriguez, Hanane Ennajdaoui, Paige Baldwin
Publikováno v:
Cancer Research. 81:LB105-LB105
CAR T cells are highly effective at inducing remissions in patients with refractory B cell malignancies. The ex vivo process used to manufacture these therapies limits patient access and exposes T cells to non-physiologic conditions in culture. Viral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9060fe6670dabb0084870caeaeacae6e
https://doi.org/10.1158/1538-7445.am2021-lb105
https://doi.org/10.1158/1538-7445.am2021-lb105
Autor:
Cori Gorman, Cailin E. Joyce, Matthew Hancock, Vidur Patel, Thomas Horn, Benjamin Duckless, Dhan Chand, Jennifer Buell, David Savitsky, Elena Paltrinieri, Margaret Wilkens, Sudesh Pawaria, Bishnu P. Joshi, Antoine Tanne, Simarjot Pabla, Sylvia Vincent, Daniel L. Levey, Andrew Basinski
Publikováno v:
Cancer Research. 80:922-922
Immune checkpoint blockade (ICB) of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death receptor 1 (PD-1) have shown durable responses in cancer patients. However, responses have been limited to a small subset of patients, and resistance t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32031c89cc7a0a33d050aab783df1f3e
https://doi.org/10.1158/1538-7445.am2020-922
https://doi.org/10.1158/1538-7445.am2020-922